This article is more than 5 years old. Information may no longer be current.

IOPtima, Meheco partner to distribute glaucoma laser-based system in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RAMAT GAN, Israel — IOPtima has signed a cooperation and distribution agreement with China Meheco Corporation to bring its IOPtiMate laser system to the Chinese market, according to a press release from the company.

"The IOPtiMate has the potential to revolutionize glaucoma treatment in China by way of presenting a cost efficient and reproducible long-term solution for patients," Joshua Degani, PhD, CEO of IOPtima, said in the release. "We see Meheco as an ideal partner with whom to address the Chinese market, not only due to their experience with SFDA approvals of new technologies, but also due to Meheco's deep involvement in the health care system in China."

IOPtima, a Bio-Light Life Sciences subsidiary, has entered into an exclusive cooperation agreement with Meheco to distribute the company's OT-135 laser-based system in China. The system is a noninvasive filtration treatment for glaucoma.

In the agreement, Meheco received responsibility for registration and the regulatory approval process with the Chinese medical regulatory authority, the SFDA. IOPtima will assist in the approval process.

The companies will also conduct a pilot and demonstration study of the IOPtiMate in China.